DHEA
DHEA is the most abundant circulating steroid in young adults, made mostly by the adrenal glands and converted in tissues into testosterone and estrogens. Its blood level falls steadily from the mid-20s, which made it an obvious anti-aging candidate. Long-term trials did not find that benefit, and DHEA remains a hormone sold over the counter.
This page contains affiliate links. Titrate earns a small commission when you purchase through them, at no cost to you. This does not affect our recommendations.
What It Does
The adrenal cortex releases DHEA, and most of it is sulfated to DHEA-S, a stable reservoir and the form labs measure. Tissues convert DHEA to androstenedione and then to testosterone or, through aromatase, to estrogens, using the hormone locally before it ever appears in the blood. In women, a large share of androgen activity comes from this pathway, and after menopause nearly all of it does. In men, the testes supply most testosterone and DHEA adds relatively little. DHEA-S peaks in the 20s and falls to about 20% of that peak by the 70s and 80s (Orentreich 1984).
Dose determines what DHEA does. At 50 mg daily, it restored youthful DHEA-S levels in middle-aged and older adults and roughly doubled androgen levels in women, with little change in men (Morales 1994). In women with adrenal insufficiency, who lack adrenal androgens altogether, 50 mg daily improved well-being and sexual interest (Arlt 1999). In healthy older adults, the results were negative: two years of 75 mg in men and 50 mg in women did not improve body composition, physical performance, insulin sensitivity, or quality of life (Nair 2006). The Endocrine Society advises against routine DHEA in women because of insufficient evidence of benefit and unknown long-term safety (Wierman 2014). One route does have FDA approval: intravaginal prasterone, the drug name for DHEA, treats painful intercourse after menopause (Labrie 2016).
Replacement-range doses of 5-25 mg aim to return DHEA-S to the normal range for age. Doses of 50-100 mg push many women above the normal androgen range, with acne, oily skin, unwanted hair, and in some cases voice changes that may not reverse. In men, higher doses raise estradiol. Monitoring means DHEA-S, testosterone, estradiol, and SHBG before starting and a few weeks after; the Testosterone Metabolism Model shows how DHEA feeds into those downstream hormones.
Forms and Bioavailability
Absorption ratings are broad tiers. Head-to-head human trials rarely support a finer ranking among well-absorbed forms.
| Form | Absorption | Typical dose | Cost |
|---|---|---|---|
| DHEA (Micronized)prasterone, dehydroepiandrosterone | HighWell absorbed orally; sulfated to DHEA-S in liver and adrenal and converted to androgens and estrogens in peripheral tissue. | 5-25 mg daily (replacement range) | Low |
| 7-Keto-DHEA7-oxo-DHEA | VariableA DHEA metabolite that is not converted to testosterone or estrogen. | 100-200 mg daily | Moderate |
Micronized DHEA is the standard oral form, taken in the morning to mirror the natural daily rhythm. 7-keto-DHEA is a metabolite that does not convert to sex hormones; it is sold for metabolism and weight loss on minimal human evidence. Wild yam products marketed as "natural DHEA" contain diosgenin, which the human body cannot convert to DHEA. Label accuracy has been a problem: an analysis of DHEA products found contents ranging from none to well above the labeled amount (Parasrampuria 1998).
Typical Dosing
Replacement-range doses are 5-25 mg daily; adrenal insufficiency trials used 25-50 mg. Doses of 50-100 mg push androgens above the normal range in many women. Check DHEA-S and sex hormones before starting and again after 4-8 weeks.
What to Look For
Measure DHEA-S first. If it is low for age and symptoms fit, a replacement dose of 5-25 mg in the morning is the starting point, with a recheck in four to eight weeks. Choose a product with third-party verification given the history of label inaccuracy.
Do not use DHEA with breast, prostate, ovarian, or uterine cancer, in pregnancy, or with polycystic ovary syndrome, where androgens are already high. DHEA is on the World Anti-Doping Agency prohibited list, and it is prescription-only in many countries outside the US.
Red flags: wild yam "DHEA precursors," testosterone booster blends containing DHEA, and 50-100 mg doses taken without labs. Green flags: micronized DHEA, a stated dose of 25 mg or less, third-party testing, and a plan for follow-up labs.
DHEA (Micronized)
The form used in the trials. Low doses with lab follow-up are the reasonable use.
What to look for: Micronized DHEA, 5-25 mg per capsule, USP or NSF verified.
Find on iHerb Affiliate link7-Keto-DHEA
Avoids sex hormone conversion, and with it most of the evidence.
What to look for: Only if you have a specific reason; 100 mg doses, and it is still banned in sport.
Find on iHerb Affiliate linkProducts on Titrate
994 of the 214,745 labels in the NIH Dietary Supplement Label Database list DHEA as an active ingredient (482 on market). 715 are sold as DHEA products by name.
Top on-market labels, ranked by label completeness and simplicity:
DHEA does not have its own search category yet. Each product above links to its full label in the NIH database.
Related Tools
References
MedlinePlus, National Library of Medicine. DHEA.
Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551-555.
Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78(6):1360-1367.
Parasrampuria J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 1998;280(18):1565.
Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341(14):1013-1020.
Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647-1659.
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.
Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256.
Stay current.
Get updates when the evidence changes. No spam, no sales.